Applying Key Updates from ESC/HFA to Managing Heart Failure

Applying Key Updates from ESC/HFA to Managing Heart Failure

Applying Key Updates from ESC/HFA to Managing Heart Failure

Are you up to date with the latest strategies for maintaining optimal RAASi therapy for your patients with heart failure and multiple comorbidities?

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.

    In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Gregg C. Fonarow, MD

    Interim Chief
    Ronald Reagan UCLA Medical Center
    Los Angeles, CA 

    Contracted Research: NIH, NHLBI
    Consulting Fees: Amgen, Cytokinetics, Janssen, Medtronic, Merck, Novartis

    Andrew J. S. Coats, MD

    Director of the Monash Warwick Alliance 
    Academic Vice-President
    Monash University, Australia and University of Warwick, UK

    Honoraria/Lecture Fees: Abbott, Actimed, Arena, Astra Zeneca, Boehringer Ingelheim, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Impulse Dynamics, Menarini, Novartis, Respicardia, Servier, Viatris, Vifor Pharma

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • James Seternus, DO, has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Review key updates to the ESC/HFA guidelines for optimizing RAASi therapy and managing hyperkalemia (HK) in patients with heart failure (HF)
    • Evaluate the role of potassium binders in managing recurrent HK in patients with HF
    • Discuss aspects of personalized approaches to the treatment of patients with HF
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, primary care physicians, and all other professionals involved in the identification and treatment of HF.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

    Global Learning Collaborative (GLC) designates this Podcast PLUS activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free